WELCOME to this Patient Advocacy organization's informational archive provided by MS Views and News

· Our live MS educational seminars average 72 people per educational program. SINCE our first program in February 2010, we have hosted more than 150 educational programs.

· Visit our Multiple Sclerosis Learning channel on YouTube archived by topic here: www.youtube.com/msviewsandnews

* Be Empowered with beneficial Multiple Sclerosis (MS) information - See our listings of upcoming Educational Programs --

Visit MS Views and News.org

joomla ecommerce template

Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information



Friday, November 2, 2012

The Lancet criticizes Sanofi for cost of Lemtrada, withdrawal of Campath

PARIS (Reuters) - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators.
The journal, which published the encouraging results of two late-stage Lemtrada tests on Thursday, also criticized the drugmaker's decision to withdraw leukemia therapy Campath, the same drug given at a different dosage, depriving MS patients who had been using it off-label.
In an editorial accompanying the test results, The Lancet voiced concerns that Lemtrada would be priced higher than current MS drugs on the market and said the discontinuation of Campath may mean patients who had used it for MS would not be able to continue their treatment.
The injectable drug, chemically known as alemtuzumab, was sold until September 2012 under the name Campath as treatment for leukemia and given more frequently at a higher dosage.

Read more: http://medcitynews.com/2012/10/the-lancet-criticizes-sanofi-for-cost-of-lemtrada-withdrawal-of-campath/#ixzz2B6jj3dCc


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register

No comments: